PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26022F0171Cerdelga eliglustat 84mg ORAL capsule — Genzyme Corp

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Feb 28, 2023 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

260-Network Contract Office 20 (36C260)

Awarding office

Genzyme Corp

Recipient

Feb 28, 2023

PoP end

$241K

Obligated

$261K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Genzyme Corp — $90

Contract facts

Federal

Contract number36C26022F0171

Also listed as36C260-22-F-0171

Also listed as36F79719D0153-36C26022F0171

Agency260-Network Contract Office 20 (36C260)

Awarding office260-Network Contract Office 20 (36C260)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentGenzyme Corp

CAGE1HBD8

UEIX2XMAQLR9DA8

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79719D0153

Place of performanceCAMBRIDGE MA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startMar 1, 2022

PoP end (current)Feb 28, 2023

Obligated$241K

Current value$261K

Potential value$261K

ELIGLUSTAT (CERDELGA) 84MG ORAL CAPSULE UD, 56CAPSULES/PACKAGE NDC: 58468-0220-01 is a federal award for 260-Network Contract Office 20 (36C260) held by Genzyme Corp. Estimated value $261K ($241K obligated). Current period of performance ends Feb 28, 2023. Last award drew 1 bidder. Place of performance: CAMBRIDGE MA.

ELIGLUSTAT (CERDELGA) 84MG ORAL CAPSULE UD, 56CAPSULES/PACKAGE NDC: 58468-0220-01

Recompete timing

Public

● Past PoP end (1270 days ago)

Current PoP ended Feb 28, 2023 (1270 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26022F0171?

36C26022F0171 (Cerdelga eliglustat 84mg ORAL capsule) is a 260-Network Contract Office 20 (36C260) award with a potential value of $261K, currently held by Genzyme Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C260-22-F-0171?

36C260-22-F-0171 is the dashed form of PIID 36C26022F0171 (Cerdelga eliglustat 84mg ORAL capsule), held by Genzyme Corp. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26022F0171?

260-Network Contract Office 20 (36C260) awarded 36C26022F0171 to Genzyme Corp (potential $261K).

Who is the incumbent on 36C26022F0171?

Genzyme Corp is the incumbent. The current period of performance ends Feb 28, 2023.

When does Genzyme Corp’s 36C26022F0171 come up for recompete?

SCOUT tracks a period-of-performance end of Feb 28, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Oct 12, 2023 · refreshed monthly